KALY - New Cannabis Biotech On Scene With Near Term PPS Potential To $0.10
December 21 2018 - 10:49AM
InvestorsHub NewsWire
New York, NY
-- December 21, 2018 -- InvestorsHub NewsWire -- Kali, Inc.
(USOTC:
KALY) executed a reverse merger last month acquiring a patented
cannabis extraction asset. As the company cleans up its
filings and updates its website, it is becoming clear that there is
a lot here under the hood. Not only does the company have a
patented cannabis extraction process, it has a substantial amount
of research behind cannabis extracts derived from the patented
extraction process. The company just release news this week
(see below) on research conducted with Beach Tree Labs and Brown
University for a cannabis extract therapy for respiratory
diseases. This research was intended as an example of more
research yet to be disclosed. The news indicated further
research study information would be forthcoming. The company
has already attracted the attention of Generex Biotechnology
(OTCQB:
GNBT) that has FDA trials underway with the likes of Merck
(NYSE: MRK). If KALY’s partnership with GNBT advances to trial
stage or if GNBT signs a second pharmaceutical company, KALY can
arguably justify a $100 million valuation and $0.10 PPS. Even
now, with preclinical research results for a respiratory condition
with an $11 billion therapy market, where a 1 percent penetration
of that market would be over $1 billion dollars, KALY can justify a
higher valuation today than the current PPS. Comparing KALY
to other OTC quoted biotechs; taking into account the OTC
transparency concerns, but also considering the $400,000 in revenue
contracts (see below) KALY has recently announced, a $0.05 PPS
today does not seem out of the question.
KALY
Highlights:
Kali-Extracts, Inc. Releases
Preclinical Research Study Results on Therapy for Respiratory
Disease Driving $11 Billion Treatment Market
Kali-Extracts Inc. Announces
$300,000 Contract to Produce Hemp-Derived CBD Extract for Puration
Inc.
KALY - Kali-Extracts Announces
$100,000 Order of its Hemp4mula CBD Infused Chewing Gum Available
Soon on USMJ E-commerce Site
Kali-Extracts and Nouveau Announce
100 Acer Hemp Farm and CBD Extraction Facility Made Possible By New
Farm Bill
KALY Short
Squeeze
The KALY PPS has gone in
the last month from $0.003 to over $0.03. As with any such
meteoric, the trading has attracted its fair share of short
sellers. In fact, KALY has been reported all week as one of
the top 11 most shorted stocks on the OTC. Yesterday, the PPS
dropped below $0.02 as a result of a short raid, but not on a lot
of volume. The PPS popped at the open today almost going back
to $0.03. There is definitely a short squeeze here and if all
that KALY has under the hood gets a little more market attention,
the short cover will contribute to pushing the KALY PPS to the
$0.05 it arguably deserves today and maybe even
higher.
US Cannabis
Health
KALY is partners with Puration, Inc. (USOTC:
PURA) and Nouveau Life Pharmaceuticals, Inc. (USOTC:
NOUV) in a joint venture named US Cannabis Health for the
purpose of together developing partnerships with pharmaceutical
companies to develop cannabis pharmaceuticals. US Cannabis
Health recently announced its first agreement with Generex
Biotechnology, Corp. (OTCQB:
GNBT).
Learn more about Kali, Inc. at www.kali-extracts.com.
Disclaiemer:
NextBigTicker.com
(NBT)is a third party publisher and news dissemination service
provider. NBT is NOT affiliated in any manner with any company
mentioned herein. NBT is news dissemination solutions provider and
are NOT a registered broker/dealer/analyst/adviser, holds no
investment licenses and may NOT sell, offer to sell or offer to buy
any security. NBT's market updates, news alerts and corporate
profiles are NOT a solicitation or recommendation to buy, sell or
hold securities. The material in this release is intended to be
strictly informational and is NEVER to be construed or interpreted
as research material. All readers are strongly urged to perform
research and due diligence on their own and consult a licensed
financial professional before considering any level of investing in
stocks. All material included herein is republished content
and details which were previously disseminated by the companies
mentioned in this release or opinion of the writer. NBT is not
liable for any investment decisions by its readers or subscribers.
Investors are cautioned that they may lose all or a portion of
their investment when investing in stocks. NBT has not been
compensated for this release and HOLDS NO SHARES OF ANY
COMPANY NAMED IN THIS RELEASE.
Disclaimer/Safe Harbor:
This news release contains forward-looking statements within the
meaning of the Securities Litigation Reform Act. The statements
reflect the Company's current views with respect to future events
that involve risks and uncertainties. Among others, these risks
include the expectation that any of the companies mentioned herein
will achieve significant sales, the failure to meet schedule or
performance requirements of the companies' contracts, the
companies' liquidity position, the companies' ability to obtain new
contracts, the emergence of competitors with greater financial
resources and the impact of competitive pricing. In the light of
these uncertainties, the forward-looking events referred to in this
release might not occur.
Source: www.nextbigticker.com
Nouveau Life Pharmaceuti... (PK) (USOTC:NOUV)
Historical Stock Chart
From Mar 2024 to Apr 2024
Nouveau Life Pharmaceuti... (PK) (USOTC:NOUV)
Historical Stock Chart
From Apr 2023 to Apr 2024